Please assess the completion status of the following clinical trial:

Trial Title: Phase 4 IOP Signals Associated With ILUVIEN®

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are eligible for treatment with ILUVIEN based on the Prescribing Information.~Exclusion Criteria:~* Patients who are unable to understand and sign the Informed Consent Form.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ILUVIEN 0.19 MG (Type: EXPERIMENTAL): All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).